Bank Of America Corp I Mab Transaction History

Bank Of America Corp

$1.19 Trillion
Q3 2024

A detailed history of Bank Of America Corp transactions in I Mab stock. As of the latest transaction made, Bank Of America Corp holds 568 shares of IMAB stock, worth $533. This represents 0.0% of its overall portfolio holdings.

Number of Shares

568

Previous 568 -0.0%

Holding current value

$533

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.58 - $1.9 $28,896 - $34,749	-18,289 Reduced 96.99%	568 $0
Q1 2024 May 15, 2024	SELL	$1.54 - $2.37 $36,303 - $55,870	-23,574 Reduced 55.56%	18,857 $35,000
Q4 2023 Feb 14, 2024	SELL	$1.21 - $1.9 $769,307 - $1.21 Million	-635,791 Reduced 93.74%	42,431 $80,000
Q2 2023 Aug 14, 2023	SELL	$2.95 - $3.85 $9,201 - $12,008	-3,119 Reduced 0.46%	678,222 $2.03 Million
Q1 2023 May 12, 2023	SELL	$3.08 - $7.39 $492,938 - $1.18 Million	-160,045 Reduced 19.02%	681,341 $2.36 Million
Q4 2022 Feb 10, 2023	SELL	$3.22 - $4.86 $81,636 - $123,215	-25,353 Reduced 2.93%	841,386 $3.52 Million
Q3 2022 Nov 14, 2022	SELL	$4.01 - $12.34 $378,002 - $1.16 Million	-94,265 Reduced 9.81%	866,739 $3.48 Million
Q2 2022 Aug 12, 2022	BUY	$8.27 - $18.43 $709,359 - $1.58 Million	85,775 Added 9.8%	961,004 $10.9 Million
Q1 2022 May 16, 2022	BUY	$12.54 - $46.93 $1.35 Million - $5.07 Million	107,996 Added 14.08%	875,229 $14.2 Million
Q4 2021 Feb 08, 2022	BUY	$45.28 - $74.5 $9.91 Million - $16.3 Million	218,768 Added 39.89%	767,233 $36.4 Million
Q3 2021 Nov 15, 2021	BUY	$57.18 - $84.43 $810,240 - $1.2 Million	14,170 Added 2.65%	548,465 $39.8 Million
Q2 2021 Sep 13, 2021	BUY	$47.86 - $83.95 $25.6 Million - $44.9 Million	534,295 New	534,295 $44.9 Million

Others Institutions Holding IMAB

# of Institutions

Shares Held

15.5M

Call Options Held

56.4K

Put Options Held

5.8K

View Full List

About I-Mab

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $78.1M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

More about IMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp I Mab Transaction History